Details

The use of continuous glucose monitoring in people living with obesity, intermediate hyperglycemia or type 2 diabetes
ID Battelino, Tadej (Author), et al.

.pdfPDF - Presentation file, Download (872,57 KB)
MD5: FEAB3D31FF6B35CFFA0CB943E22D3230
URLURL - Source URL, Visit https://www.sciencedirect.com/science/article/pii/S0168822725001251 This link opens in a new window

Abstract
A global trend towards increased obesity, intermediate hyperglycemia (previously termed prediabetes) and type 2 diabetes, has prompted a range of international initiatives to proactively raise awareness and provide action-driven recommendations to prevent and manage these linked disease states. One approach, that has shown success in managing people already diagnosed with type 2 diabetes mellitus, is to use continuous glucose monitoring (CGM) devices to help them manage their chronic condition through understanding and treating their daily glucose fluctuations, in assocation with glucose-lowering medications, including insulin. However, much of the burden of type 2 diabetes mellitus is founded in the delayed detection both of type 2 diabetes mellitus itself, and the intermediate hyperglycemia that precedes it. In this review, we provide evidence that using CGM technology in people at-risk of intermediate hyperglycemia or type 2 diabetes mellitus can significantly improve the rate and timing of detection of dysglycemia. Earlier detection allows intervention, including through continued use of CGM to guide changes to diet and lifestyle, that can delay or prevent harmful progression of early dysglycemia. Although further research is needed to fully understand the cost-effectiveness of this intervention in people at-risk or with early dysglycemia, the proposition for use of CGM technology is clear.

Language:English
Keywords:continuous glucose monitoring, consensus statements, intermediate hyperglycemia, obesity, prediabetes, type 2 diabetes
Work type:Article
Typology:1.02 - Review Article
Organization:MF - Faculty of Medicine
Publication status:Published
Publication version:Version of Record
Year:2025
Number of pages:12 str.
Numbering:Vol. 223, art. 112111
PID:20.500.12556/RUL-181976 This link opens in a new window
UDC:616.379
ISSN on article:1872-8227
DOI:10.1016/j.diabres.2025.112111 This link opens in a new window
COBISS.SI-ID:250818563 This link opens in a new window
Publication date in RUL:21.04.2026
Views:320
Downloads:168
Metadata:XML DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Diabetes research and clinical practice
Publisher:Elsevier
ISSN:1872-8227
COBISS.SI-ID:23224837 This link opens in a new window

Licences

License:CC BY-NC-ND 4.0, Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Link:http://creativecommons.org/licenses/by-nc-nd/4.0/
Description:The most restrictive Creative Commons license. This only allows people to download and share the work for no commercial gain and for no other purposes.

Projects

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P3-0343
Name:Etiologija, zgodnje odkrivanje in zdravljenje bolezni pri otrocih in mladostnikih

Funder:UKRI - UK Research and Innovation
Funding programme:MRC
Project number:MR/W030004/1
Name:Using mesenchymal stromal cell secretory products to improve human islet transplantation

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back